Search

Matthew John Kasztejna

Examiner (ID: 13619, Phone: (571)272-6086 , Office: P/3779 )

Most Active Art Unit
3779
Art Unit(s)
3795, 3779, 3739, 3993, 3799
Total Applications
1245
Issued Applications
699
Pending Applications
148
Abandoned Applications
418

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 20386573 [patent_doc_number] => 12486290 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => Isoindolinone and indazole compounds for the degradation of EGFR [patent_app_type] => utility [patent_app_number] => 19/205510 [patent_app_country] => US [patent_app_date] => 2025-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 134503 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 386 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19205510 [rel_patent_id] =>[rel_patent_doc_number] =>)
19/205510
Isoindolinone and indazole compounds for the degradation of EGFR May 11, 2025 Issued
Array ( [id] => 19682247 [patent_doc_number] => 20250000792 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS [patent_app_type] => utility [patent_app_number] => 18/883447 [patent_app_country] => US [patent_app_date] => 2024-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46548 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18883447 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/883447
DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS Sep 11, 2024 Pending
Array ( [id] => 19629609 [patent_doc_number] => 20240408058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => COMPOSITIONS FOR THE EFFECTIVE TREATMENT OF VITAMIN C DEFICIENCY-RELATED DISEASES AND OTHER CONDITIONS [patent_app_type] => utility [patent_app_number] => 18/809240 [patent_app_country] => US [patent_app_date] => 2024-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 279 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18809240 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/809240
COMPOSITIONS FOR THE EFFECTIVE TREATMENT OF VITAMIN C DEFICIENCY-RELATED DISEASES AND OTHER CONDITIONS Aug 18, 2024 Pending
Array ( [id] => 19599465 [patent_doc_number] => 20240390345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA [patent_app_type] => utility [patent_app_number] => 18/795731 [patent_app_country] => US [patent_app_date] => 2024-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26155 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18795731 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/795731
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea Aug 5, 2024 Issued
Array ( [id] => 19599463 [patent_doc_number] => 20240390343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA [patent_app_type] => utility [patent_app_number] => 18/795683 [patent_app_country] => US [patent_app_date] => 2024-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18795683 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/795683
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea Aug 5, 2024 Issued
Array ( [id] => 19777386 [patent_doc_number] => 12226406 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea [patent_app_type] => utility [patent_app_number] => 18/795711 [patent_app_country] => US [patent_app_date] => 2024-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26142 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18795711 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/795711
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea Aug 5, 2024 Issued
Array ( [id] => 20082956 [patent_doc_number] => 20250212892 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-03 [patent_title] => USE OF THERMALLY HYDROLYZED KERATIN PEPTIDE SOLUTION IN ENHANCING THE YIELD AND QUALITY OF TEA LEAVES [patent_app_type] => utility [patent_app_number] => 18/758140 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 0 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18758140 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/758140
USE OF THERMALLY HYDROLYZED KERATIN PEPTIDE SOLUTION IN ENHANCING THE YIELD AND QUALITY OF TEA LEAVES Jun 27, 2024 Pending
Array ( [id] => 19947036 [patent_doc_number] => 12318374 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-03 [patent_title] => Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea [patent_app_type] => utility [patent_app_number] => 18/758007 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21900 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18758007 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/758007
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea Jun 27, 2024 Issued
Array ( [id] => 19510497 [patent_doc_number] => 20240342183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => LAMOTRIGINE ORAL LIQUID SUSPENSION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/752293 [patent_app_country] => US [patent_app_date] => 2024-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 212 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18752293 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/752293
LAMOTRIGINE ORAL LIQUID SUSPENSION AND USE THEREOF Jun 23, 2024 Pending
Array ( [id] => 19768275 [patent_doc_number] => 20250049701 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => SILK-BASED ARTICLES HAVING VARIABLE ACTIVE AGENT RELEASE RATES [patent_app_type] => utility [patent_app_number] => 18/746604 [patent_app_country] => US [patent_app_date] => 2024-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10933 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18746604 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/746604
SILK-BASED ARTICLES HAVING VARIABLE ACTIVE AGENT RELEASE RATES Jun 17, 2024 Pending
Array ( [id] => 19510401 [patent_doc_number] => 20240342087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => TARGETED EXTRACELLULAR VESICLES COMPRISING MEMBRANE PROTEINS WITH ENGINEERED GLYCOSYLATION SITES [patent_app_type] => utility [patent_app_number] => 18/731681 [patent_app_country] => US [patent_app_date] => 2024-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17802 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18731681 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/731681
TARGETED EXTRACELLULAR VESICLES COMPRISING MEMBRANE PROTEINS WITH ENGINEERED GLYCOSYLATION SITES Jun 2, 2024 Pending
Array ( [id] => 19570268 [patent_doc_number] => 20240374560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => FIBER-ENHANCED LIPOSOME AND METHODS [patent_app_type] => utility [patent_app_number] => 18/662189 [patent_app_country] => US [patent_app_date] => 2024-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9430 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18662189 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/662189
FIBER-ENHANCED LIPOSOME AND METHODS May 12, 2024 Pending
Array ( [id] => 19379448 [patent_doc_number] => 20240269318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => NANO-DELIVERY SYSTEMS COMPRISING MODIFIED LIPIDS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/626620 [patent_app_country] => US [patent_app_date] => 2024-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18626620 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/626620
NANO-DELIVERY SYSTEMS COMPRISING MODIFIED LIPIDS AND USE THEREOF Apr 3, 2024 Pending
Array ( [id] => 19331283 [patent_doc_number] => 20240245713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => LONG-ACTING INJECTABLE FORMULATIONS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/626241 [patent_app_country] => US [patent_app_date] => 2024-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8360 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18626241 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/626241
LONG-ACTING INJECTABLE FORMULATIONS AND USE THEREOF Apr 2, 2024 Pending
Array ( [id] => 19279801 [patent_doc_number] => 20240216273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => TOPICAL ANESTHETIC [patent_app_type] => utility [patent_app_number] => 18/608602 [patent_app_country] => US [patent_app_date] => 2024-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3128 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18608602 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/608602
TOPICAL ANESTHETIC Mar 17, 2024 Pending
Array ( [id] => 19446514 [patent_doc_number] => 20240306644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => STABLE CHLORINATED ALKALINE PRODUCTS [patent_app_type] => utility [patent_app_number] => 18/606407 [patent_app_country] => US [patent_app_date] => 2024-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5264 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18606407 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/606407
STABLE CHLORINATED ALKALINE PRODUCTS Mar 14, 2024 Pending
Array ( [id] => 19554694 [patent_doc_number] => 20240366486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => HYDROPHOBIC SYNTHETIC MELANIN NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 18/601746 [patent_app_country] => US [patent_app_date] => 2024-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18601746 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/601746
HYDROPHOBIC SYNTHETIC MELANIN NANOPARTICLES Mar 10, 2024 Pending
Array ( [id] => 19570494 [patent_doc_number] => 20240374786 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => NANOFIBER AND MICROFIBER HYBRID AEROGELS [patent_app_type] => utility [patent_app_number] => 18/600263 [patent_app_country] => US [patent_app_date] => 2024-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19992 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18600263 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/600263
NANOFIBER AND MICROFIBER HYBRID AEROGELS Mar 7, 2024 Pending
Array ( [id] => 19263462 [patent_doc_number] => 20240207159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => SKIN PENETRATION IMPROVER [patent_app_type] => utility [patent_app_number] => 18/589817 [patent_app_country] => US [patent_app_date] => 2024-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18589817 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/589817
SKIN PENETRATION IMPROVER Feb 27, 2024 Pending
Array ( [id] => 19246700 [patent_doc_number] => 20240197684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS [patent_app_type] => utility [patent_app_number] => 18/443689 [patent_app_country] => US [patent_app_date] => 2024-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 98483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443689 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/443689
Non-sedating dexmedetomidine treatment regimens Feb 15, 2024 Issued
Menu